
## Hypothetical, simplified examples of cost-effectiveness analysis


## With QALYs:



WTP per QALY: \$20,000

Treatment	Total cost	Total QALYs	Incremental cost	Incremental QALYs gained	ICER	Net monetary benefit	Net health benefit (QALYs)
No Treatment	\$0	1.4	-	-	-	\$28,000	1.4
Drug A	\$15,000	2.6	\$15,000	1.2	\$12,500	\$37,000	1.85
Drug B	\$50,000	3.9	\$35,000	1.3	\$26,923	\$28,000	1.4

## With DALYs:



DALY	Standard life expectancy: 7							WTP per DALY: \$20,000	
						Incremental			Net hea

	Total DALYs	Total DALYs		Incremental DALYs		Net monetary	Net health benefit
Total cost	incurred	averted	cost	averted	ICER	benefit	(DALYs)
\$0	5.6	1.4	-	-	-	\$28,000	1.4
\$15,000	4.4	2.6	\$15,000	1.2	\$12,500	\$37,000	1.85
\$50,000	3.1	3.9	\$35,000	1.3	\$26,923	\$28,000	1.4
	\$0 \$15,000	Total cost incurred   \$0 5.6   \$15,000 4.4	Total cost incurred averted   \$0 5.6 1.4   \$15,000 4.4 2.6	Total cost incurred averted cost   \$0 5.6 1.4 -   \$15,000 4.4 2.6 \$15,000	Total cost Total DALYs incurred Total DALYs averted Incremental cost DALYs averted   \$0 5.6 1.4 - -   \$15,000 4.4 2.6 \$15,000 1.2	Total cost Total DALYs incurred Total DALYs averted Incremental cost DALYs averted ICER   \$0 5.6 1.4 - - - -   \$15,000 4.4 2.6 \$15,000 1.2 \$12,500	Total cost Total DALYs incurred Total DALYs averted Incremental cost DALYs averted ICER Net monetary benefit   \$0 5.6 1.4 - - - \$28,000   \$15,000 4.4 2.6 \$15,000 1.2 \$12,500 \$37,000